Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E-merge: Mepolizumab-based Regimen vs Conventional Therapy in EGPA
2024-513653-75-00Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Prednisone dose ≤4.0 mg/day without relapse at day 168. Started May 2022; status: completed.
02
Drugs
mepolizumab
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on 2024-513653-75-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513653-75-00.